C
Cornelis J A Punt
Researcher at Utrecht University
Publications - 22
Citations - 1931
Cornelis J A Punt is an academic researcher from Utrecht University. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 5, co-authored 22 publications receiving 1605 citations. Previous affiliations of Cornelis J A Punt include University of Washington.
Papers
More filters
Journal ArticleDOI
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Steven J. Cohen,Cornelis J A Punt,Nicholas Iannotti,B. H. Saidman,Kert D. Sabbath,Nashat Y. Gabrail,Joel Picus,Michael A. Morse,Edith P. Mitchell,M. Craig Miller,Gerald V. Doyle,H. Tissing,Leon W.M.M. Terstappen,Neal J. Meropol +13 more
TL;DR: The number of CTCs before and during treatment is an independent predictor of PFS and OS in patients with metastatic colorectal cancer and Baseline and follow-up CTC levels remained strong predictors of P FS and OS after adjustment for clinically significant factors.
Journal ArticleDOI
Advanced analytics and artificial intelligence in gastrointestinal cancer: a systematic review of radiomics predicting response to treatment.
Nina J. Wesdorp,Tessa Hellingman,Elise P. Jansma,Jan-Hein T. M. van Waesberghe,Ronald Boellaard,Cornelis J A Punt,J. Huiskens,Geert Kazemier +7 more
TL;DR: Radiomics has great potential to help predict response to treatment and improve patient selection and early adjustment of treatment strategy in a non-invasive manner, as demonstrated in this review.
Journal ArticleDOI
Chromosomal copy number heterogeneity predicts survival rates across cancers.
Erik van Dijk,Tom van den Bosch,Kristiaan J. Lenos,Khalid El Makrini,Lisanne E. Nijman,Hendrik F. van Essen,Nico Lansu,Michiel Boekhout,Joris H. Hageman,Rebecca C. Fitzgerald,Cornelis J A Punt,Jurriaan B. Tuynman,Hugo J. Snippert,Geert J. P. L. Kops,Jan Paul Medema,Bauke Ylstra,Louis Vermeulen,Daniël M. Miedema +17 more
TL;DR: In this paper, a scalable measure of chromosomal copy number heterogeneity (CNH) was introduced to predict patient survival across cancers, and the level of ITH can be derived from a single-sample copy number profile.
Journal ArticleDOI
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
Erik van Dijk,Hedde D Biesma,Martijn Cordes,Dominiek Smeets,Maarten Neerincx,Sudipto Das,Paul P. Eijk,Verena Murphy,Anna Barat,Orna Bacon,Jochen Prehn,Johannes Betge,Timo Gaiser,Bozena Fender,Gerrit A. Meijer,Deborah McNamara,Rut Klinger,Miriam Koopman,Matthias P. Ebert,E. Kay,Bryan T Hennessey,Henk M.W. Verheul,William M. Gallagher,Darran O'Connor,Cornelis J A Punt,Fotios Loupakis,Diether Lambrechts,Annette T. Byrne,Nicole Ct Grieken,Bauke Ylstra +29 more
TL;DR: It is concluded that the loss of chromosome 18q11.2-q12.1 is consistently predictive for prolonged PFS in patients receiving bevacizumab and is substantiated by a significant gain in OS and overall response rate.
Journal ArticleDOI
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Koen P. Rovers,Checca Bakkers,Simon W. Nienhuijs,Jacobus W. A. Burger,Geert-Jan Creemers,Anna M.J. Thijs,Alexandra R. M. Brandt-Kerkhof,Eva V. E. Madsen,Esther van Meerten,Jurriaan B. Tuynman,Miranda Kusters,Kathelijn S. Versteeg,Arend G. J. Aalbers,Niels F. M. Kok,Tineke E. Buffart,Marinus J. Wiezer,Djamila Boerma,Maartje Los,Philip R. de Reuver,Andreas J A Bremers,Henk M.W. Verheul,Schelto Kruijff,Derk Jan A. de Groot,Arjen J. Witkamp,Wilhelmina M U van Grevenstein,Miriam Koopman,Joost Nederend,Max J. Lahaye,Onno Kranenburg,Remond J.A. Fijneman,Iris van 't Erve,Petur Snaebjornsson,Patrick H. J. Hemmer,Marcel G. W. Dijkgraaf,Cornelis J A Punt,Pieter J. Tanis,Ignace H. J. T. de Hingh +36 more
TL;DR: In this article, the feasibility and safety of perioperative systemic therapy in patients with resectable colorectal peritoneal metastases and the response of CPM to neoadjuvant treatment were evaluated.